deltatrials
Completed PHASE2 INTERVENTIONAL NCT00003259

Vinorelbine in Treating Patients With Metastatic Prostate Cancer

Master Protocol for Metastatic Hormone-Resistant Prostatic Carcinoma Phase II Trials Protocol 4: Vinorelbine

Sponsor: Swiss Cancer Institute

Conditions Prostate Cancer
Interventions vinorelbine tartrate
Updated 8 times since 2017 Last updated: Jun 24, 2019 Started: Oct 31, 1997 Primary completion: Sep 30, 1999 Completion: Sep 30, 1999
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Prostate Cancer, this trial is completed. The trial is conducted by Swiss Cancer Institute and has accumulated 8 data snapshots since 1997. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jul 2019 · 13 months · monthly snapshotCompleted~Jul 2019 – ~Jan 2021 · 18 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Aug 2025 · 11 months · monthly snapshotCompleted~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshotCompleted~Sep 2025 – present · 9 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Aug 2025 — Sep 2025 [monthly]

    Completed PHASE2

  3. Sep 2024 — Aug 2025 [monthly]

    Completed PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

▶ Show 3 earlier versions

  1. Jul 2019 — Jan 2021 [monthly]

    Completed PHASE2

  2. Jun 2018 — Jul 2019 [monthly]

    Completed PHASE2

  3. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Oct 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Swiss Cancer Institute
Data source: Swiss Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations